BioTime Inc. (BTX) reported the completion of enrollment in a safety trial evaluating Renevia, an injectable matrix designed to facilitate the stable engraftment of transplanted cells. The ten healthy volunteers each received one subcutaneous injection of Renevia without cells. The primary objective of the trial is to determine the safety, tolerability, and acceptance of Renevia without cells as determined by monitoring subjects for any post-treatment reactions. Examinations of the subjects after they received Renevia injections have shown that Renevia was well-tolerated by all subjects with no serious adverse events or subject withdrawals, the company said. A final check of the enrolled subjects for adverse events will be made four weeks after the injection.
The Renevia safety study was initiated on October 7, 2013.
For comments and feedback: editorial@rttnews.com